TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03644108
Drug: Mucinex® ER 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Mucinex® 600 mg ER Bi-Layer tablet
Study: NCT02170038
Drug: Microgynon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
Study: NCT02170038
Drug: Noristerat(BAY86-6308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
Study: NCT01825720
Drug: (Glucose-Insulin-Potassium)GIK group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
Study: NCT00592670
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
Study: NCT00592670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
Study: NCT01998399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Study: NCT03126578
Drug: LEO 32731
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 32731 is being developed by LEO Pharma.
Study: NCT01061320
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
Study: NCT00650182
Drug: fentanyl; naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00599235
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times daily for 7 days
Study: NCT00154115
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02876679
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
Study: NCT02876679
Drug: Conditioning regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
Study: NCT01711658
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
Study: NCT00719537
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tab Daily
Study: NCT04347278
Drug: Patients with the treatment agains COVID19
Normalized name: The New Parent First Aid KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data will be collected from patients who receive any of the treatments included in the Technical Document. Manejo clínico del COVID-19: tratamiento médico of the Ministry of Health, and Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise.
Study: NCT01557504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
Study: NCT01641718
Drug: Tissue glue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
Study: NCT03386552
Drug: Isifera+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer
Study: NCT03386552
Drug: Buffer
Normalized name: Buffers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertubation solution of Ringer-Acetate buffer
Study: NCT00841269
Drug: Uridine
Normalized name: Uridine
DrugBank: Uridine (DB02745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uridine 500 mg by mouth twice per day for 6 weeks
Study: NCT02855138
Drug: oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02659475
Drug: PHEN/TPM ER (Qsymia®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHEN/TPM ER (Qsymia®)
Study: NCT05317260
Drug: Antiviral Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
Study: NCT02174419
Drug: Placebo tablets BID
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets BID administered for 10 weeks
Study: NCT01034202
Drug: Norditropin® SimpleXx®
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
Study: NCT01034202
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01034202
Drug: Norditropin® SimpleXx®
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
Study: NCT03010267
Drug: Cholecaliferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT03540914
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT03291158
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
Study: NCT00125437
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01184456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per day for 90 days.
Study: NCT01635608
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 500 mg paracetamol
Study: NCT00953225
Drug: Placebo daily for one year
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00092677
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 4 years
Study: NCT01090102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth).
Study: NCT02708992
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03111342
Drug: Anesthesia
Normalized name: anesthesia tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 2% lidocaine without vasoconstrictor injection into the cervix
Study: NCT04616092
Drug: FEFINJECT
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FEFINJECT injection
Study: NCT01628393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule taken once a day
Study: NCT02001688
Drug: Kamada-AAT for Inhalation, 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02001688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02001688
Drug: Kamada-AAT for Inhalation, 160mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00858936
Drug: IK-1001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
Study: NCT00858936
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
Study: NCT04231513
Drug: E2814
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2814, intravenous infusion.
Study: NCT01831804
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
Study: NCT01831804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to off-white smooth ointment for topical application as single or repeat doses.
Study: NCT04503863
Drug: NPC-22
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of middle dose NPC-22
Study: NCT04503863
Drug: NPC-22
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of high dose NPC-22
Study: NCT04503863
Drug: NPC-22 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of NPC-22 Placebo
Study: NCT01629628
Drug: 6 Mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.~--------------------------------------------------------------------------------
Study: NCT00003508
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01751126
Drug: NOVA22007 ''Ciclosporin''
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
Study: NCT01751126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
Study: NCT03588091
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: 400mg orally daily;
Study: NCT00728455
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study: NCT00728455
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study: NCT00728455
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study: NCT00728455
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
Study: NCT00728455
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
Study: NCT03606785
Drug: placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive a placebo of 100 mL 0.9% normal saline
Study: NCT00400374
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib, 400 mg, daily for 6 months.
Study: NCT00648791
Drug: Proscar Tablets 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg, single dose fasting
Study: NCT02623062
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contents of 2 sachets taken four times daily for 7 days
Study: NCT01371604
Drug: IDX184
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 50 mg tablet administered orally
Study: NCT03492515
Drug: Platelet Concentrate
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: according to the their conditions, use if necessary
Study: NCT03374254
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
Study: NCT03374254
Drug: 5-Fluorouracil [5-FU]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/m\^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m\^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
Study: NCT00278057
Drug: dialysisis with and without glucose in the dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02308969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing mannitol looking identical to LSD
Study: NCT02242812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02323412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets 1x3 for 100 days (oral intake).
Study: NCT04435912
Drug: Hydrocortisone 200mg IV
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine
Study: NCT00860795
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 25 ml daily in 2 divided doses for 10 days
Study: NCT03494712
Drug: S 95010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of S 95010 in healthy volunteers
Study: NCT00495391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oral placebo tablet twice daily for 52 weeks.
Study: NCT00821561
Drug: Nexagon® vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05496205
Drug: iN1011-N17
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached.
Study: NCT05496205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for each formulations
Study: NCT03627117
Drug: Verum
Normalized name: ILLICIUM VERUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water
Study: NCT03627117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
Study: NCT01253629
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
Study: NCT01253629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication identical in appearance to active medication was provided
Study: NCT02394600
Drug: Grastek®
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet daily for four months
Study: NCT02394600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet daily for four months
Study: NCT03139851
Drug: Cyclophosphamide 50mg
Normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One tablet per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT00456339
Drug: Prednisolone and amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
Study: NCT01355809
Drug: Inhalation gas
Normalized name: INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
Study: NCT01664156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03748485
Drug: adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
Study: NCT00050622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03841526
Drug: Glugaon RTU Injection Without Insulin Pump Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg injection without pump reduction
Study: NCT01715272
Drug: Fleet enema
Normalized name: Fleet Enema
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00268463
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2
Study: NCT00517218
Drug: Genasense® (, oblimersen sodium G3139)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00405561
Drug: AMT2003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00153179
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT02336048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
Study: NCT03371251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration
Study: NCT01068613
Drug: QAX028
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAX028 60 mcg via inhalation device
Study: NCT01068613
Drug: QAX028
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAX028 20 mcg via inhalation device
Study: NCT01068613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to QAX028 via inhalation device
Study: NCT02726334
Drug: BNC101 Solution for Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration: Administered via IV infusion once a week over 60 minutes (1 hour).
Study: NCT03656666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets
Study: NCT01473264
Drug: recombinant human CC10 (rhCC10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
Study: NCT01473264
Drug: recombinant human CC10 (rhCC10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
Study: NCT01473264
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
Study: NCT01782924
Drug: KHK4827
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01040845
Drug: Norethindrone/Ethinyl Estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
Study: NCT02025049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: mannitol-based DP-b99 look-alike
Study: NCT00503698
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected s.c (under the skin)
Study: NCT01364012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
Study: NCT00682786
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00471679
Drug: ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no